Cargando…

Chondroitin polymerizing factor (CHPF) promotes development of malignant melanoma through regulation of CDK1

Chondroitin polymerizing factor (CHPF) is an important member of glycosyltransferases involved in the biosynthesis of chondroitin sulfate (CS). However, the relationship between CHPF and malignant melanoma (MM) is still unknown. In this study, it was demonstrated that CHPF was up-regulated in MM tis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Wei, Zhao, Fang, Xu, Yu, Huang, Kai, Guo, Xianling, Zheng, Biqiang, Liu, Xin, Luo, Zhiguo, Kong, Yunyi, Xu, Midie, Schadendorf, Dirk, Chen, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329816/ https://www.ncbi.nlm.nih.gov/pubmed/32612115 http://dx.doi.org/10.1038/s41419-020-2526-9

Ejemplares similares

Chondroitin Polymerizing Factor (CHPF) promotes cell proliferation and tumor growth in human osteosarcoma by inhibiting SKP2's ubiquitination while activating the AKT pathway
por: Shen, Yi, et al.
Publicado: (2022)

Expression of CHPF modulates cell proliferation and invasion in lung cancer
por: Cao, Chengsong, et al.
Publicado: (2020)

The HNF4A-CHPF pathway promotes proliferation and invasion through interactions with MAD1L1 in glioma
por: Luo, Haitao, et al.
Publicado: (2023)

CHPF promotes gastric cancer tumorigenesis through the activation of E2F1
por: Lin, Xiaolin, et al.
Publicado: (2021)

Knockdown of CHPF suppresses cell progression of non-small-cell lung cancer
por: Hou, Xiao-Ming, et al.
Publicado: (2019)

Bioinformatics and Experimental Analysis of the Prognostic and Predictive Value of the CHPF Gene on Breast Cancer
por: Li, Wan-Wan, et al.
Publicado: (2022)

CHPF Regulates the Aggressive Phenotypes of Hepatocellular Carcinoma Cells via the Modulation of the Decorin and TGF-β Pathways
por: Liu, Chiung-Hui, et al.
Publicado: (2021)

Four Immune-Related Genes (FN1, UGCG, CHPF2 and THBS2) as Potential Diagnostic and Prognostic Biomarkers for Carbon Nanotube-Induced Mesothelioma
por: Xie, Dongli, et al.
Publicado: (2021)

The interplay of CDK4 and CDK6 in melanoma
por: Kollmann, Karoline, et al.
Publicado: (2019)

Neurocan, an extracellular chondroitin sulfate proteoglycan, stimulates neuroblastoma cells to promote malignant phenotypes
por: Su, Zhendong, et al.
Publicado: (2017)

T-Cell Mediated Immune Responses Induced in ret Transgenic Mouse Model of Malignant Melanoma
por: Abschuetz, Oliver, et al.
Publicado: (2012)

Clinical features and prognosis of patients with metastatic ocular and orbital melanoma: A bi‐institutional study
por: Liu, Xin, et al.
Publicado: (2023)

Dacarbazine-Loaded Targeted Polymeric Nanoparticles for Enhancing Malignant Melanoma Therapy
por: Xiong, Wei, et al.
Publicado: (2022)

Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms
por: Yang, Jianbo, et al.
Publicado: (2004)

Immunohistochemical detection of the chondroitin sulfate proteoglycan 4 protein in primary and metastatic melanoma
por: Grossauer, Anna, et al.
Publicado: (2023)

Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?
por: Bouwhuis, Marna G., et al.
Publicado: (2009)

Immunotherapy in non-melanoma skin cancer: updates and new perspectives
por: Ascierto, Paolo Antonio, et al.
Publicado: (2019)

Cryostructuring of Polymeric Systems: 62 Preparation and Characterization of Alginate/Chondroitin Sulfate Cryostructurates Loaded with Antimicrobial Substances †
por: Vernaya, Olga I., et al.
Publicado: (2022)

TMED3 promotes the development of malignant melanoma by targeting CDCA8 and regulating PI3K/Akt pathway
por: Guo, Xianling, et al.
Publicado: (2023)

Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma
por: Helfrich, Iris, et al.
Publicado: (2010)

Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma
por: Helfrich, Iris, et al.
Publicado: (2013)

Association of Inherited Variation in Toll-Like Receptor Genes with Malignant Melanoma Susceptibility and Survival
por: Gast, Andreas, et al.
Publicado: (2011)

Heterologous production of chondroitin
por: Couto, Márcia R., et al.
Publicado: (2022)

Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies
por: Utikal, Jochen, et al.
Publicado: (2007)

The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma
por: Albrecht, Lea Jessica, et al.
Publicado: (2023)

Chondroitin polymerizing factor promotes breast carcinoma cell proliferation, invasion and migration and affects expression of epithelial‐mesenchymal transition‐related markers
por: Li, Yang, et al.
Publicado: (2021)

Chondroitin Sulfate and Fucosylated Chondroitin Sulfate as Stimulators of Hematopoiesis in Cyclophosphamide-Induced Mice
por: Ustyuzhanina, Nadezhda E., et al.
Publicado: (2021)

Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo
por: de Bruyn, Marco, et al.
Publicado: (2010)

Delayed Skin Allergy to Glucosamine Chondroitin Supplement
por: Chu, Eric Chun-Pu, et al.
Publicado: (2023)

A Highly Active Chondroitin Sulfate Lyase ABC for Enzymatic Depolymerization of Chondroitin Sulfate
por: Fan, Xiao-Man, et al.
Publicado: (2022)

THE OCCURRENCE OF INTRACELLULAR CHONDROITIN SULFATE
por: Thorp, Frank K., et al.
Publicado: (1963)

INTRACELLULAR SYNTHESIS OF CHONDROITIN SULFATE
por: Dziewiatkowski, Dominic D.
Publicado: (1962)

Holothurian Fucosylated Chondroitin Sulfate
por: Pomin, Vitor H.
Publicado: (2014)

Glucosamine and chondroitin for the treatment of osteoarthritis
por: Vasiliadis, Haris S, et al.
Publicado: (2017)

Chondroitin Sulfate Safety and Quality
por: Volpi, Nicola
Publicado: (2019)

Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas.
por: Maelandsmo, G. M., et al.
Publicado: (1996)

Expression of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma cells is downregulated upon inhibition of BRAF
por: Uranowska, Karolina, et al.
Publicado: (2021)

Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma
por: Ascierto, Paolo A, et al.
Publicado: (2022)

Common Nevus and Skin Cutaneous Melanoma: Prognostic Genes Identified by Gene Co-Expression Network Analysis
por: Yang, Lingge, et al.
Publicado: (2019)

Antitumour potential of BPT: a dual inhibitor of cdk4 and tubulin polymerization
por: Mahale, S, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9ecgpdep01f87a817bp6kmtvn6